Open Access and Peer-reviewed
Home Journal Issues Guide for Authors Editorial Board Aims & Scope About Journal News & Announcements


Original Research 
RMJ. 2020; 45(3): 611-615


Oral versus topical propranolol in infantile hemangiomas

Abdul Hameed Khan, Gulwish Salah u Din, Jawaria Irshad, Anam Altaf.

Abstract
Objective: To determine the therapeutic response rate of oral and topical propranolol in infantile hemangiomas (IH).
Methodology: A sample size of 60 patients was calculated using WHO calculator. Non probability consecutive sampling was used. Ethical approval and consent forms were taken. Patients were randomly divided into two groups using lottery method. Group A was given oral propranolol and Group B was given topical timolol. Both groups were followed for 3 months for Visual analogue scale of therapeutic response rate. Data was analyzed using SPSS version 24. Chi-square test was applied. P value ≤0.05 was considered significant.
Results:Total 60 infantile hemangioma patients were included in study. Mean age of patients was 5.4months±1.9SD. There were 32(53.3%) male and 28(46.7%) female. Therapeutic response rate was higher in topical timolol as compare to oral propranolol (p=0.003). Adverse effects were significantly higher in oral propranolol group as compare to topical timolol (p=0.000).
Conclusion: Topical timolol is safe and effective treatment in infantile hemangiomas as compare to oral propranolol. Topical timolol poses less risk of inducing adverse effects among infants. Therefore, topical propranolol is recommended for small and superficial infantile hemangiomas.

Key words: Infantile hemangiomas, propranolol, response rate.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Abdul Hameed Khan
Articles by Gulwish Salah u Din
Articles by Jawaria Irshad
Articles by Anam Altaf
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Khan AH, Din GSu, Irshad J, Altaf A. Oral versus topical propranolol in infantile hemangiomas. RMJ. 2020; 45(3): 611-615.


Web Style

Khan AH, Din GSu, Irshad J, Altaf A. Oral versus topical propranolol in infantile hemangiomas. http://www.rmj.org.pk/?mno=87871 [Access: September 02, 2020].


AMA (American Medical Association) Style

Khan AH, Din GSu, Irshad J, Altaf A. Oral versus topical propranolol in infantile hemangiomas. RMJ. 2020; 45(3): 611-615.



Vancouver/ICMJE Style

Khan AH, Din GSu, Irshad J, Altaf A. Oral versus topical propranolol in infantile hemangiomas. RMJ. (2020), [cited September 02, 2020]; 45(3): 611-615.



Harvard Style

Khan, A. H., Din, . G. S. u., Irshad, . J. & Altaf, . A. (2020) Oral versus topical propranolol in infantile hemangiomas. RMJ, 45 (3), 611-615.



Turabian Style

Khan, Abdul Hameed, Gulwish Salah u Din, Jawaria Irshad, and Anam Altaf. 2020. Oral versus topical propranolol in infantile hemangiomas. Rawal Medical Journal, 45 (3), 611-615.



Chicago Style

Khan, Abdul Hameed, Gulwish Salah u Din, Jawaria Irshad, and Anam Altaf. "Oral versus topical propranolol in infantile hemangiomas." Rawal Medical Journal 45 (2020), 611-615.



MLA (The Modern Language Association) Style

Khan, Abdul Hameed, Gulwish Salah u Din, Jawaria Irshad, and Anam Altaf. "Oral versus topical propranolol in infantile hemangiomas." Rawal Medical Journal 45.3 (2020), 611-615. Print.



APA (American Psychological Association) Style

Khan, A. H., Din, . G. S. u., Irshad, . J. & Altaf, . A. (2020) Oral versus topical propranolol in infantile hemangiomas. Rawal Medical Journal, 45 (3), 611-615.








AUTHOR LOGIN

REVIEWER LOGIN

Indexed
&
Abstracted


Indexed in WHO Index Medicus IMEMR, Emromedex, Pakmedinet, ExtraMED,  Scopus and Web of Science

                     Approved by the Higher Education Commission of Pakistan 


ABOUT JOURNAL
POLICIES
STATEMENTS

This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access.

The articles in Rawal Medical Journal are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.